OTHER (INCOME)/EXPENSE, NET - Schedule Of Other Income Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Alliance Statement [Line Items]
Interest expense (Note 10)	$ 521	$ 282	$ 946	$ 570
Royalty and licensing income (Note 4)	(191)	(340)	(352)	(703)
Royalty income - divestiture (Note 4)	(265)	(218)	(536)	(406)
Investment income	(87)	(95)	(270)	(197)
Litigation and other settlements (a)	69	(7)	71	(332)
Provision for restructuring (Note 6)	260	113	480	180
Integration expenses	74	59	145	126
Equity investment (gain)/losses (Note 9)	(107)	58	(209)	213
Acquisition expense (Note 4)	1	0	50	0
Other	(2)	32	29	20
Other (income)/expense, net	273	$ (116)	$ 354	(529)
Nimbus Therapuetics TYK2 Inhibitor
Alliance Statement [Line Items]
Other				$ 400
Eisai
Alliance Statement [Line Items]
Collaboration arrangement, termination payment received	$ 90